Acurx Pharmaceuticals Valuation
Is ACXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Book vs. similares
Price-To-Book vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of ACXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de ACXP para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de ACXP para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACXP?
Other financial metrics that can be useful for relative valuation.
| What is ACXP's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$31.51m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ACXP's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.5x | ||
MRKR Marker Therapeutics | 2.9x | n/a | US$40.5m |
AURX Nuo Therapeutics | 59.7x | n/a | US$43.4m |
CYTH Cyclo Therapeutics | 8.2x | 63.8% | US$39.1m |
VIRX Viracta Therapeutics | 3.3x | 22.1% | US$42.8m |
ACXP Acurx Pharmaceuticals | 6.8x | 7.4% | US$31.5m |
Price-To-Book vs. similares: ACXP es un buen valor basado en su Ratio Price-To-Book (6.6x) comparado con la media de sus homólogos (254.3x).
Price to Earnings Ratio vs Industry
How does ACXP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs. Industria: ACXP es caro en función de su Ratio Price-To-Book (10.3x) en comparación con la media del sector US Biotechs (2.1x).
Price to Book Ratio vs Fair Ratio
What is ACXP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.8x |
| Fair PB Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular ACXP's Price-To-Book Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.00 | US$11.45 +472.5% | 9.0% | US$12.35 | US$10.00 | n/a | 3 |
| Mar ’25 | US$2.96 | US$12.12 +309.3% | 13.5% | US$14.00 | US$10.00 | n/a | 3 |
| Feb ’25 | US$3.26 | US$12.59 +286.1% | 13.0% | US$14.00 | US$10.00 | n/a | 4 |
| Jan ’25 | US$3.83 | US$12.67 +230.7% | 14.9% | US$14.00 | US$10.00 | n/a | 3 |
| Dec ’24 | US$3.79 | US$12.33 +225.4% | 13.8% | US$14.00 | US$10.00 | n/a | 3 |
| Nov ’24 | US$5.07 | US$12.33 +143.3% | 13.8% | US$14.00 | US$10.00 | n/a | 3 |
| Oct ’24 | US$1.50 | US$11.33 +655.6% | 27.3% | US$14.00 | US$7.00 | n/a | 3 |
| Sep ’24 | US$1.85 | US$11.33 +512.6% | 27.3% | US$14.00 | US$7.00 | n/a | 3 |
| Aug ’24 | US$1.98 | US$13.33 +573.4% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Jul ’24 | US$2.65 | US$13.33 +403.1% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Jun ’24 | US$2.95 | US$13.33 +352.0% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| May ’24 | US$2.95 | US$13.33 +352.0% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Apr ’24 | US$3.46 | US$13.33 +285.4% | 7.1% | US$14.00 | US$12.00 | US$2.28 | 3 |
| Mar ’24 | US$3.30 | US$13.33 +304.0% | 7.1% | US$14.00 | US$12.00 | US$2.96 | 3 |
| Feb ’24 | US$3.56 | US$13.33 +274.5% | 7.1% | US$14.00 | US$12.00 | US$3.26 | 3 |
| Jan ’24 | US$3.98 | US$13.33 +235.0% | 7.1% | US$14.00 | US$12.00 | US$3.83 | 3 |
| Dec ’23 | US$3.13 | US$13.00 +315.3% | 7.7% | US$14.00 | US$12.00 | US$3.79 | 2 |
Pronóstico de los analistas: El precio objetivo es más de un 20% superior al precio actual de la acción y los analistas están dentro de un rango de acuerdo estadísticamente seguro.